Latest News From Lumira Ventures

New Data Confirms Cardiac Dimensions’ Carillon® System Shows Favorable Long-Term Survival Rate In Patients

Jennifer Schram Cardiac Dimensions, Main Page, Portfolio News, Press Release

KIRKLAND, Wash. — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the findings of a post hoc analysis of pooled prospectively collected data from three …

Antios Therapeutics Initiates First-in-Human Phase 1 Study of ATI-2173

Jennifer Schram Antios Therapeutics, Main Page, Portfolio News, Press Release

ATLANTA /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase 1 clinical trial for ATI-2173, a novel liver-targeted, orally-administered, …

Aurinia Demonstrates Voclosporin’s Superiority over Standard-of-Care in Lupus Nephritis

Jennifer Schram Aurinia Pharmaceuticals, Main Page, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced positive efficacy and safety results from its pivotal …

Notch Therapeutics Announces R&D Collaboration with Allogene worth up to $283M per Target

Jennifer Schram Main Page, Notch Therapeutics, Portfolio News, Press Release

SOUTH SAN FRANCISCO, Calif. and TORONTO — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, …

Satsuma Pharmaceuticals Completes $90.8M Initial Public Offering

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

SOUTH SAN FRANCISCO, Calif. — Satsuma Pharmaceuticals, Inc. (“Satsuma” or the “Company”) (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced the closing of the Company’s previously announced initial public offering …